Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
DICLOXACILLIN SODIUM CAPSULES | PERFORMANCE TESTS | USP42–NF37 | 1330 | 28-Feb-2020 | 1-Mar-2020 | NA | NA | In Dissolution <711>: Change Sample solution: Sample per the chapter. Dilute with Medium to a concentration that is similar to the Standard solution. Tolerances: NLT 75% (Q) of the labeled amount of… Read More |
ALFADEX | CHEMICAL INFORMATION | USP42–NF37 | 5561 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | Change 972.84 to: 972.85 |
MEROPENEM FOR INJECTION | ASSAY/Procedure | Second Supplement to USP42–NF37 | 9216 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | In Mobile phase: Change Solution A to: Buffer |
POLYETHYLENE GLYCOL | CHEMICAL INFORMATION | USP42–NF37 | 5882 | 31-Jan-2020 | 1-Feb-2020 | NA | NA | See https://www.uspnf.com/sites/default/files/usp_pdf/EN/january-2020-errata-with-image.pdf for correction |
CYPROHEPTADINE HYDROCHLORIDE ORAL SOLUTION | IMPURITIES/Organic Impurities | USP42–NF37 | 1195 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In Standard solution: Change in Solution B to: in Diluent |
<121> INSULIN ASSAYS | ASSAY/Rabbit Blood Sugar Method—Quantitative | Revision Bulletin (Official May 01, 2019) | Online | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In Standard stock solution: Change of USP Insulin RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In Sample stock solution: Change of USP Insulin RS of the appropriate species.… Read More |
CUPRIC CHLORIDE | REAGENTS AND REFERENCE TABLES/Reagent Specifications | USP42–NF37 | 6092 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | Change [7447-39-4]. to: [10125-13-0]. |
<857> ULTRAVIOLET-VISIBLE SPECTROSCOPY | QUALIFICATION OF UV-VIS SPECTROMETERS | Second Supplement to USP42–NF37 | 9570 | 27-Dec-2019 | 1-Jan-2020 | NA | NA | In all instances in Table 4: Change < to: ≤ AND In Control of Photometric Response/Acidic Nicotinic Acid Solutions in 0.1 N Hydrochloric Acid/paragraph 1: Change Using nicotinic acid solutions, the absorbance accuracy… Read More |
SIMVASTATIN TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP42–NF37 | 4009 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Standard solution: Change USP Simvastatin RS in Medium to: USP Simvastatin RS in Medium. Transfer a portion of the solution to a centrifuge tube containing about 10 mg of Prewashed manganese dioxide per milliliter of… Read More |
<1227> VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES | VALIDATION OF NEUTRALIZATION METHODS—RECOVERY COMPARISONS | Second Supplement to USP42–NF37 | 9616 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In paragraph 1 in Recovery on Agar Medium: Change If it is necessary to solubilize the test stample, to: If it is necessary to solubilize the test sample, |
MEFENAMIC ACID CAPSULES | PERFORMANCE TESTS/Dissolution <711> | USP42–NF37 | 2711 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Solution A, Mobile phase, Standard solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay, making any necessary volumetric adjustments. to: … Read More |
0.1 N POTASSIUM HYDROXIDE VS | REAGENTS AND REFERENCE TABLES/Solutions | USP42–NF37 | 6185 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Standardization: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N potassium hydroxide VS. Titrate with 0.1 N hydrochloric acid VS until a permanent pale-pink color is produced. to: Standardization: Add 2 drops of phenolphthalein TS… Read More |
ROPINIROLE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | Revision Bulletin (Official July 01, 2019) | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Test 2 and Test 3 in Analysis: Change Result1 = C1 × (1/L) × (Mr1/Mr2) × 100 to: Result1 = C1 × V × (1/L… Read More |
ZIPRASIDONE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 3/Tier 2 | Revision Bulletin (Official October 01, 2019) | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Buffer: Change 6.8 g/L g to: 6.8 g/L AND In Standard stock solution 2: Change Standard stock solution to: Standard stock solution 1 |
<1430> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—GENERAL | 1. OVERVIEW: GENERAL CHAPTERS BASED ON SCATTERING PHENOMENA | Second Supplement to USP42–NF37 | 9634 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Row 6 of Column 4 in Table 1: Change Also properties of condensated phrases to: Also properties of condensated phases |
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS | IMPURITIES/Organic Impurities | Second Supplement to USP42–NF37 | 9101 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Table 4, Footnote h: Change 0.47, to: 0.45, |
25% TETRABUTYLAMMONIUM HYDROXIDE TS | REAGENTS AND REFERENCE TABLES/Solutions | Second Supplement to USP42–NF37 | 9336 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change Transfer about 34.82 g to: Transfer about 77.1 g |
SODIUM BICARBONATE | IMPURITIES/Carbonate/Analysis | USP42–NF37 | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Remove the external reference to a reagent in Sodium Bicarbonate |
2,5-DIHYDROXYBENZOIC ACID | REAGENTS AND REFERENCE TABLES/Reagent Specifications | USP42–NF37 | 6097 | 22-Nov-2019 | 1-Dec-2019 | NA | NA | Change [303-07-1]. to: [490-79-9]. |
<1430.5> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—SMALL ANGLE X-RAY SCATTERING AND SMALL ANGLE NEUTRON SCATTERING | 6. EXPERIMENTAL CONSIDERATIONS | Second Supplement to USP42–NF37 | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In 6.2 Resolution/6.2.1 Size resolution: Change qmin < π/dmax π/dmax to: qmin < π/dmax |
<1228.4> DEPYROGENATION BY RINSING | ROUTINE PROCESS CONTROL | USP42–NF37 | 8067 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the first paragraph: Change WFI to: Water for Injection |
<55> BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS | D-VALUE DETERMINATION | USP42–NF37 | 6385 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the third paragraph in Procedure: Change stated spore filter to: stated spore titer |
GADOTERIDOL | Limit of gadoteridol related compound A | USP42–NF37 | 2020 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Chromatographic system: Change packing L21 to: packing L47 |
<1229.2> STEAM STERILIZATION OF AQUEOUS LIQUIDS | BIOBURDEN/BIOLOGICAL INDICATOR METHOD/Routine Process Control | USP42–NF37 | 8082 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In the first paragraph: Change calibrartion to: calibration |
<1222> TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE | INTRODUCTION | USP42–NF37 | 8021 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In paragraphs 4 and 5: Change a probability of a PNSU to: a PNSU |
HYPROMELLOSE ACETATE SUCCINATE | ASSAY | USP42–NF37 | 5772 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Content of Methoxy and 2-Hydroxypropoxy Groups/Analysis: Change Result = (rUM/rSM) × (CS/CU) × (Mr1/Mr2) to: Result… Read More |
<2022> MICROBIOLOGICAL PROCEDURES FOR ABSENCE OF SPECIFIED MICROORGANISMS—NUTRITIONAL AND DIETARY SUPPLEMENTS | BUFFER AND MEDIA/Media | USP42–NF37 | 8514 | 25-Oct-2019 | 1-Nov-2019 | NA | NA | In Row 5 of Column 2 for L-Cystine in Fluid Selenite–Cystine Medium: Change 10.0 g to: 10.0 mg |
AMIODARONE HYDROCHLORIDE | CHEMICAL INFORMATION | USP42–NF37 | 253 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | See https://www.uspnf.com/sites/default/files/usp_pdf/EN/september-2019-errata-with-image.pdf for correction. |
DESFLURANE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 1230 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In USP Desflurane Related Compound A RS: Change Bis-(1,2,2,2-tetrafluoroethyl)ether. to: Bis-(1,2,2,2-tetrafluoroethyl)ether; Also known as: 1,1,1,2-Tetrafluoro-2-(1,2,2,2-tetrafluoroethoxy)ethane. |
BENZALDEHYDE | ASSAY/Procedure | USP42–NF37 | 5586 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In Chromatographic system: Delete Detector temperature: 25° |
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 487 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In USP Bendamustine Related Compound B RS: Change 4-(1-Methyl-5-morpholino-1H-benzimidazol-2-yl)butanoic acid. C16H21N3O3 303.36 to: 4-(1-Methyl-5-morpholino-1H-benzimidazol-2-yl)… Read More |
ZINC SULFATE | CHEMICAL INFORMATION | USP42–NF37 | 4649 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | Change Zinc sulfate (1:1) monohydrate 179.46 to: Zinc sulfate (1:1) monohydrate 179.45 [7446-19-7]. AND Change 287.56 to: 287.54 |
ANAGRELIDE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Analysis | USP42–NF37 | 329 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | Change Result = (rU/rS) x (CS/CU) x (Mr1/Mr2) x (V/L) x 100 to: Result = (rU/rS) x… Read More |
HYDROCHLOROTHIAZIDE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP42–NF37 | 2171 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In Empty capsules solution: Change Place 10 Capsules to: Place 10 empty capsules |
PENICILLAMINE CAPSULES | PERFORMANCE TESTS/Dissolution <711> | Revision Bulletin (Official June 11, 2019) | Online | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In Procedure for a pooled sample/Analysis: Change Result = (AU/AS) × (CS/CU) × V × (1/L) × 100 to: Result = (AU/AS… Read More |
DESFLURANE | CHEMICAL INFORMATION | USP42–NF37 | 1230 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | Change (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether to: (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane. |
ASHWAGANDHA ROOT DRY EXTRACT | COMPOSITION/Content of Withanolides | USP42–NF37 | 4724 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In the first equation in Analysis: Change CS = concentration of USP Withanoside IV RS in Standard solution A (mg/mL) to: CS = concentration of USP Withanolide A RS in Standard solution A (mg/… Read More |
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | IMPURITIES/Organic Impurities | USP42–NF37 | 487 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In Table 2: Change Bendamustine related compound B to: Bendamustine related compound Ba AND Change Bendamustine related compound Ca to: Bendamustine related compound Cb AND Change … Read More |
TRIFLUOPERAZINE HYDROCHLORIDE TABLETS | Assay | USP42–NF37 | 4473 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | Change 2(407.51/480.43)C(rU/rS) to: 2000(407.51/480.43)C(rU/rS) |
PAROXETINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | First Supplement to USP42–NF37 | 8788 | 27-Sep-2019 | 1-Oct-2019 | NA | NA | In USP Paroxetine Related Compound G RS: Change 405.46 to: 441.92 |
FEXOFENADINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 1828 | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic… Read More |
LEVOFLOXACIN | CHEMICAL INFORMATION | USP42–NF37 | 2552 | 30-Aug-2019 | 1-Sep-2019 | NA | NA | Change Anhydrous [100986-85-41]. to: Anhydrous [100986-85-4]. |
CHLOROQUINE PHOSPHATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 939 | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In USP Chloroquine Related Compound G RS: Change C18H26Cl3NO · H2SO4 to: C18H26ClN3O · H2SO4 |
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official August 01, 2018) | Online | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic… Read More |
OLMESARTAN MEDOXOMIL TABLETS | IMPURITIES/Organic Impurities | Revision Bulletin (Official March 19, 2019) | Online | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In the Analysis: Change CS = concentration of in the Standard solution (mg/mL) to: CS = concentration of USP Olmesartan Medoxomil RS in the Standard solution (mg/mL) |
FEXOFENADINE HYDROCHLORIDE CAPSULES | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 1830 | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl. C32H37NO4 538.12 to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl… Read More |
SILDENAFIL CITRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP42–NF37 | 4002 | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In USP Sildenafil Related Compound A RS: Change 5-[2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2-methylpropyl)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one. C23H32N6O4S… Read More |
CIDOFOVIR INJECTION | IMPURITIES/Organic Impurities | USP42–NF37 | 981 | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In Table 1: Change 0.56 to: 0.59 |
MECLOFENAMATE SODIUM | CHEMICAL INFORMATION | USP42–NF37 | 2706 | 30-Aug-2019 | 1-Sep-2019 | NA | NA | Change 336.15 to: 336.14 AND Change [6385-02-0]; to: [67254-91-5]; AND Change UNII: 9MMQ0YER4E. to: UNII: 94NJ818U2W. |
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES | IMPURITIES/Organic Impurities | USP42–NF37 | Online | 30-Aug-2019 | 1-Sep-2019 | NA | NA | Change Diluent, Solution A, System suitability solution, Chromatographic system, and Sample solution: Proceed as directed in the Assay. to: Diluent, Buffer solution, Solution A, … Read More |